Biosafety Level 4(BSL-4)Pathogen

Nipah Virus(NiV)Research Proteins

NiV Research Tools

Full-length Proteins •Vaccine Antigens •Therapeutic Antibody Development

Nipah virus(NiV)is a highly pathogenic zoonotic RNA virus with a fatality rate of 40-75%, listed as a WHO priority pathogen.Creative BioMart offers validated Pre-F, Post-F trimers, G protein, and N protein antigens to accelerate next-generation vaccine(mRNA-1215, ChAdOx1)and monoclonal antibody(m102.4)development.

75%

Maximum Fatality

100%

NiV-B Local CFR(Case Fatality Rate)

Approved Vaccines

1998

First Outbreak(Malaysia)

2(NiV-M/NiV-B)

Major Strains

4 in trials

Clinical-Stage Vaccines

100nm

Diameter

Need custom proteins or proteins from specific species?

We offer custom expression services for wild-type/mutant NiV proteins, including site-directed mutagenesis(such as F protein stabilization mutations L104C/I114C), special tags(Fc/Avi/Biotin), and large-scale GMP pre-production services.

Recombinant NiV NP Protein

🧪 NP-1736N

Source: E.coli

Species: NiV

Tag: Non

Conjugation:

Protein Length:

Inquiry

Recombinant NiV F (ΔTM) Protein

🧪 F-1819N

Source: HEK293

Species: NiV

Tag: Non

Conjugation:

Protein Length:

Inquiry

Recombinant NiV G (ΔTM) Protein

🧪 G-1831N

Source: HEK293

Species: NiV

Tag: Non

Conjugation:

Protein Length:

Inquiry

Recombinant NiV(strain Bangladesh 2005) G protein, His-tagged

🧪 G-5743N

Source: HEK293

Species: NiV

Tag: His

Conjugation:

Protein Length: 71-602 aa

Inquiry

Recombinant NiV(strain MCL-25-H-2892, strain MCL-19-BAT-574-4) F protein, His-tagged

🧪 F-3322N

Source: HEK293

Species: NiV

Tag: His

Conjugation:

Protein Length: 27-482 aa

Inquiry

First
<<
1
>>
Last

Latest Research&Vaccine Development

1Clinical Vaccine Platforms

mRNA-1215 Vaccine(Moderna/NIAID)

Status: Phase 1 Ongoing
Description: mRNA vaccine encoding stabilized Pre-F and G proteins using LNP technology
Key Data: 2024 Hendra@30 meeting shows cross-neutralization of NiV and HeV in vaccinated subjects
Trial ID: NCT05398796
Strategy: Prime-Boost

ChAdOx1 NiV-B(Oxford University/CEPI)

Status: Phase 1 Recruiting
Description: Chimpanzee adenovirus vector expressing NiV-B G protein
Key Data: Complete protection in hamster models against Bangladesh strain(100%fatal)
Trial ID: ISRCTN87634044
Platform: Adenoviral Vector

HenipaVax™(Auro Vaccines)

Status: Phase 1 Complete
Description: Subunit vaccine based on HeV soluble G protein(sG)with alum adjuvant
Key Data: Cross-protection with NiV(81%G protein homology)
Trial ID: NCT04199169
Platform: Protein Subunit

rVSV-NiV(Crozet BioPharma)

Status: Phase 1 Ongoing
Description: Recombinant vesicular stomatitis virus vector expressing NiV-M G protein(PHV02)
Key Data: Single-dose rapid protection in non-human primates for emergency response
Trial ID: NCT05178901
Feature: Single-Dose

2Structural Biology Advances

Pre-F Stabilization Technology

2024 structural studies show Pre-Fusion conformation induces stronger neutralizing antibodies than Post-Fusion.Disulfide bonds(L104C/I114C)and cavity-filling mutations(L172F, S191P)lock F protein in pre-fusion state, exposing critical neutralizing epitopes(e.g., mAb66 binding site).

Key Technologies:

DS-Cav1 DesignHexamer-of-TrimersDomain III Targeting

G Protein Tetramer Structure

Cryo-EM reveals NiV G protein forms homotetramers(120×200Å)with four-helix bundle stalks andβ-propeller head domains.Non-competitive antibody combinations(e.g., nAH1.3+m102.4)show synergistic effects, reducing escape mutation risks.

Key Features:

Ephrin-B2/B3 BindingHead Domain ImmunodominantAntibody Synergy

Therapeutic mAb m102.4

The only NiV therapeutic in clinical trials.Treatment on day 5 post-infection achieves 100%survival in NHPs(clinical stage).Targets G protein receptor-binding site with cross-neutralizing activity against NiV and HeV.

Clinical Data: 16 AGMs(African Green Monkeys)treated with m102.4(15 mg/kg, days 1/3/5)all survived vs.control mortality at days 8-10.

Emerging Henipavirus Threats(2024 Update)

Beyond NiV and HeV, newly discovered viruses pose additional threats:

Langya virus(LayV)Angavokely virus(AngV)MěnglàvirusCedar virus

These viruses share F/G glycoprotein structures and Ephrin-B2 receptor usage—our NiV proteins enable cross-virus research for prototype pathogen preparedness.

Applications&Solutions

Vaccine Development

Subunit vaccine immunogens
mRNA vaccine validation
Neutralizing antibody titers
Pseudovirus neutralization

Antibody Therapeutics

Therapeutic mAb screening(e.g., m102.4 analogs)
Bispecific antibody design
Epitope mapping
Cross-reactivity assessment

Diagnostics

ELISA antigens(NP protein)
Immunofluorescence assays
Lateral flow devices
Serological surveys

Structural Biology

Cryo-EM sample preparation
Receptor binding studies(Ephrin-B2)
Fusion mechanism analysis
Small molecule screening

Quality Assurance

Multi-dimensional Purity Verification

SEC-HPLC(Size Exclusion Chromatography)for aggregates and fragments
SDS-PAGE for molecular weight verification
LAL endotoxin testing: <0.1 EU/μg(Vaccine Grade: <0.01 EU/μg)

Bioactivity Validation

G Protein: Ephrin-B2 binding ELISA(EC50 validation)
F Protein: Pre-F specific mAb(e.g., mAb66)binding verification
COA and activity data provided with all batches

Conformational Specificity Guarantee

Pre-F proteins use DS-Cav1 stabilization design, verified by negative-stain EM and specific antibodies(e.g., DS7)to prevent spontaneous Post-Fusion conversion.

Quality Metrics:

SEC-HPLC Purity≥95%

Ephrin-B2 Binding(ELISA)EC50: 16-48 ng/mL

Endotoxin Level<0.1 EU/μg

Host Cell Residual DNA<10 pg/dose

Sterility TestingUSP<71>Compliant

Accelerate Nipah Virus Medical Countermeasures

Whether developing mRNA vaccines, therapeutic antibodies, or diagnostic reagents, our high-quality recombinant proteins provide reliable support for your research. Contact our technical team today for samples and custom solutions.

Service Guarantees: Global Shipping | Technical Support | Batch-to-Batch Consistency | Custom Services Available